Hoe verhoudt BIOX's PE Ratio zich tot zijn concurrenten?

BIOX is duur op basis van de Price-To-Earnings -ratio ( 127.3 x) vergeleken met het gemiddelde van de peer ( 20.3 x).

Hoe verhoudt BIOX's PE Ratio zich tot andere bedrijven in de US Chemicals industrie?

BIOX is duur op basis van de Price-To-Earnings -ratio ( 127.3 x) vergeleken met het US Chemicals -industriegemiddelde ( 25.2 x).

Wat is BIOX's PE Ratio vergeleken met zijn Fair PE Ratio? Dit is de verwachte PE Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

BIOX is duur op basis van de Price-To-Earnings Ratio ( 127.3 x) vergeleken met de geschatte Fair Price-To-Earnings Ratio ( 21.7 x).

Wat is de reële prijs van BIOX als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

BIOX ( $6.57 ) handelt boven onze schatting van [[eerlijke waarde]] ( $5.76 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

De koersdoelstelling ligt meer dan 20 % hoger dan de huidige aandelenkoers en analisten zijn het statistisch gezien met elkaar eens.

Bioceres Crop Solutions (Nasdaq:BIOX) - Aandelenkoers, Nieuws & Analyse

BIOX Overzicht aandelen

Bioceres Crop Solutions Corp. levert samen met haar dochterondernemingen oplossingen voor de productiviteit van gewassen.

Over het bedrijf

BIOX fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	4/6
Prestaties in het verleden	2/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 36.07% per jaar groeien

Analisten zijn het erover eens dat de aandelenkoers met 88.7% zal stijgen

Risicoanalyse

Rentebetalingen worden niet goed gedekt door de winsten

Winstmarges (0.7%) zijn lager dan vorig jaar (4.5%)

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

HB4 Wheat's US Approval Sparks Global Expansion And Profit Growth Surge

Key Takeaways Approval of HB4 Wheat in the US highlights significant expansion and revenue opportunities, enhancing global acceptance and credibility of HB4 technology. Focus on cash generation and strategic shifts towards financially sustainable operations in HB4 and biologicals segments aim to boost net margins and optimize capital.

View narrative

US$12.40

47.0% undervalued

10.56%

Revenue growth p.a.

5 days ago

Bioceres Crop Solutions Corp. Concurrenten

CVR Partners

NYSE:UAN

US$696.6m

Muliang Viagoo Technology

OTCPK:MULG

US$49.1m

ICL Group

NYSE:ICL

US$5.4b

Mosaic

NYSE:MOS

US$8.6b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Bioceres Crop Solutions
Historische aandelenkoersen
Huidige aandelenkoers	US$6.57
52 Week Hoogtepunt	US$14.05
52 Week Laag	US$6.48
Bèta	0.44
11 maand verandering	-15.44%
3 maanden verandering	-35.01%
1 Jaar Verandering	-38.31%
33 jaar verandering	-49.15%
5 jaar verandering	13.08%
Verandering sinds IPO	34.08%

Recent nieuws en updates

Take Care Before Jumping Onto Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Even Though It's 29% Cheaper

Sep 28

Recent updates

Take Care Before Jumping Onto Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Even Though It's 29% Cheaper

Sep 28

Bioceres' Q4 2024 Shows Challenges With HB4 Rollout, Still A Hold Despite Lower Stock Prices

Sep 17

These 4 Measures Indicate That Bioceres Crop Solutions (NASDAQ:BIOX) Is Using Debt Extensively

Aug 03

Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Popularity With Investors Is Clear

Jun 21

Here's Why Bioceres Crop Solutions (NASDAQ:BIOX) Is Weighed Down By Its Debt Load

May 09

Bioceres: A Resilient Small Cap With Conference Appearances After Thursday's Earnings

Sep 06

Bioceres Crop Solutions jumps 15% after investor pitch

Aug 23

We Think Bioceres Crop Solutions (NASDAQ:BIOX) Is Taking Some Risk With Its Debt

Apr 10

Bioceres Has Not Resolved Its Major Risks And Is Growing Based On Commodities Bullishness

Mar 31

Is Now The Time To Look At Buying Bioceres Crop Solutions Corp. (NASDAQ:BIOX)?

Mar 17

Is Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Trading At A 21% Discount?

Nov 13

Bioceres Crop Solutions (NASDAQ:BIOX) Shareholders Will Want The ROCE Trajectory To Continue

Jul 08

Estimating The Intrinsic Value Of Bioceres Crop Solutions Corp. (NASDAQ:BIOX)

Jun 16

What Does Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Share Price Indicate?

May 26

Bioceres partners with Havanna to offer consumers HB4 wheat-based sustainable products

May 10

Does Bioceres Crop Solutions (NASDAQ:BIOX) Have A Healthy Balance Sheet?

May 05

Bioceres Crop Solutions (NYSEMKT:BIOX) Shareholders Will Want The ROCE Trajectory To Continue

Apr 05

Are Investors Undervaluing Bioceres Crop Solutions Corp. (NYSEMKT:BIOX) By 22%?

Mar 10

Bioceres Crop Solutions (NYSEMKT:BIOX) Shareholders Booked A 53% Gain In The Last Year

Feb 12

Rendement voor aandeelhouders

	BIOX	US Chemicals	US Markt
7D	-6.7%	-1.9%	-1.9%
1Y	-38.3%	15.8%	30.4%

Rendement versus industrie: BIOX presteerde slechter dan de US Chemicals -sector, die het afgelopen jaar een rendement van 15.8 % opleverde.

Rendement versus markt: BIOX presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.4 % opleverde.

Prijsvolatiliteit

Is BIOX's price volatile compared to industry and market?
BIOX volatility
BIOX Average Weekly Movement	5.7%
Chemicals Industry Average Movement	4.9%
Market Average Movement	6.0%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: BIOX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van BIOX is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2001	n/a	Federico Trucco	investors.biocerescrops.com/home/default.aspx

Bioceres Crop Solutions Corp. levert, samen met haar dochterondernemingen, oplossingen voor de productiviteit van gewassen. Het is actief in de segmenten Zaad en Geïntegreerde Producten, Gewasbescherming en Gewasvoeding. Het segment Zaad en Geïntegreerde Producten levert zaadeigenschappen, kiemplanten en zaadbehandelingspakketten voor gezondere gewassen met een hogere opbrengst.

Bioceres Crop Solutions Corp. Samenvatting

Hoe verhouden de winst en inkomsten van Bioceres Crop Solutions zich tot de beurswaarde?
BIOX fundamentele statistieken
Marktkapitalisatie	US$407.89m
Inkomsten(TTM)	US$3.24m
Inkomsten(TTM)	US$464.83m

127.3x

Koers/Winstverhouding

0.9x

P/S-verhouding

Is BIOX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BIOX resultatenrekening (TTM)
Inkomsten	US$464.83m
Kosten van inkomsten	US$283.24m
Brutowinst	US$181.59m
Overige uitgaven	US$178.35m
Inkomsten	US$3.24m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 12, 2024

Winst per aandeel (EPS)	0.052
Brutomarge	39.07%
Nettowinstmarge	0.70%
Schuld/Eigen Vermogen Verhouding	74.3%

Hoe presteerde BIOX op de lange termijn?

Bekijk historische prestaties en vergelijking

BIOX Overzicht aandelen

Beloningen

Risicoanalyse

HB4 Wheat's US Approval Sparks Global Expansion And Profit Growth Surge

Bioceres Crop Solutions Corp. Concurrenten

NYSE:UAN

US$696.6m

OTCPK:MULG

US$49.1m

NYSE:ICL

US$5.4b

NYSE:MOS

US$8.6b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Bioceres Crop Solutions Corp. to Report Q1, 2025 Results on Nov 12, 2024

Price target decreased by 8.1% to US$12.40

Now 21% overvalued

Bioceres Crop Solutions Corp., Annual General Meeting, Oct 24, 2024

Take Care Before Jumping Onto Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Even Though It's 29% Cheaper

Recent updates

Bioceres Crop Solutions Corp. to Report Q1, 2025 Results on Nov 12, 2024

Price target decreased by 8.1% to US$12.40

Now 21% overvalued

Bioceres Crop Solutions Corp., Annual General Meeting, Oct 24, 2024

Take Care Before Jumping Onto Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Even Though It's 29% Cheaper

Bioceres' Q4 2024 Shows Challenges With HB4 Rollout, Still A Hold Despite Lower Stock Prices

Full year 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 12%

Bioceres Crop Solutions Corp. to Report Q4, 2024 Results on Sep 10, 2024

These 4 Measures Indicate That Bioceres Crop Solutions (NASDAQ:BIOX) Is Using Debt Extensively

Price target decreased by 9.4% to US$19.20

Consensus EPS estimates fall by 21%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Bioceres Crop Solutions Corp. Announces Brazil’s Approval of New Generation Bio-Insecticide

Bioceres Crop Solutions Corp. to Report Q3, 2024 Results on May 14, 2024

Bioceres Needs To Add Clarity Around Borrowings

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bioceres Crop Solutions (NASDAQ:BIOX) Takes On Some Risk With Its Use Of Debt

Less than half of directors are independent

Bioceres Crop Solutions Corp. to Report Q2, 2024 Results on Feb 08, 2024

Bioceres Crop Solutions Corp. to Report Q1, 2024 Results on Nov 14, 2023

Bioceres Crop Solutions Corp. announced delayed 20-F filing

Bioceres Crop Solutions Corp., Annual General Meeting, Oct 27, 2023

Does Bioceres Crop Solutions (NASDAQ:BIOX) Have A Healthy Balance Sheet?

Price target decreased by 8.1% to US$24.30

Bioceres Crop Solutions Corp. to Report Q4, 2023 Results on Sep 11, 2023

Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Popularity With Investors Is Clear

Investor sentiment improves as stock rises 17%

Third quarter 2023 earnings released: EPS: US$0.45 (vs US$0.16 loss in 3Q 2022)

Here's Why Bioceres Crop Solutions (NASDAQ:BIOX) Is Weighed Down By Its Debt Load

Bioceres Crop Solutions Corp. to Report Q2, 2023 Results on Feb 09, 2023

First quarter 2023 earnings released: EPS: US$0.011 (vs US$0.021 in 1Q 2022)

Less than half of directors are independent

First quarter 2023 earnings released: EPS: US$0.011 (vs US$0.021 in 1Q 2022)

Bioceres Crop Solutions Corp. Announces Resignation of Maria Baccarelli from Board of Directors

Bioceres Crop Solutions Corp. to Report Q1, 2023 Results on Nov 10, 2022

Bioceres Crop Solutions Corp., Annual General Meeting, Oct 27, 2022

Full year 2022 earnings released: US$0.18 loss per share (vs US$0.17 loss in FY 2021)

Bioceres: A Resilient Small Cap With Conference Appearances After Thursday's Earnings

Bioceres Crop Solutions Corp. to Report Q4, 2022 Results on Sep 08, 2022

Bioceres Crop Solutions jumps 15% after investor pitch

Price target increased to US$24.25

Bioceres Crop Solutions Corp. (NasdaqGS:BIOX) completed the acquisition of Marrone Bio Innovations, Inc. (NasdaqCM:MBII) from Ardsley Advisory Partners LP, Ospraie Ag Science LLC and others.

Bioceres Crop Solutions Corp. Announces Board Changes

Bioceres Crop Solutions Corp. Announces U.S. Food and Drug Administration Concludes Evaluation of its Proprietary Drought-Tolerant HB4® Wheat

Third quarter 2022 earnings: Revenues exceed analyst expectations

Now 21% undervalued

Bioceres Crop Solutions Corp. to Report Q3, 2022 Results on May 12, 2022

Bioceres Crop Solutions Announces Regulatory Approval of HB4® Soy in China

Less than half of directors are independent

We Think Bioceres Crop Solutions (NASDAQ:BIOX) Is Taking Some Risk With Its Debt

Bioceres Has Not Resolved Its Major Risks And Is Growing Based On Commodities Bullishness

Now 21% undervalued after recent price drop

Is Now The Time To Look At Buying Bioceres Crop Solutions Corp. (NASDAQ:BIOX)?

Now 22% undervalued after recent price drop

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Trading At A 21% Discount?

First quarter 2022 earnings released

Price target increased to US$20.75